1. Home
  2. INSM vs CASY Comparison

INSM vs CASY Comparison

Compare INSM & CASY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • INSM
  • CASY
  • Stock Information
  • Founded
  • INSM 1988
  • CASY 1959
  • Country
  • INSM United States
  • CASY United States
  • Employees
  • INSM N/A
  • CASY N/A
  • Industry
  • INSM Biotechnology: Pharmaceutical Preparations
  • CASY Diversified Commercial Services
  • Sector
  • INSM Health Care
  • CASY Miscellaneous
  • Exchange
  • INSM Nasdaq
  • CASY Nasdaq
  • Market Cap
  • INSM 17.3B
  • CASY 16.0B
  • IPO Year
  • INSM 2000
  • CASY N/A
  • Fundamental
  • Price
  • INSM $98.24
  • CASY $510.92
  • Analyst Decision
  • INSM Strong Buy
  • CASY Buy
  • Analyst Count
  • INSM 17
  • CASY 13
  • Target Price
  • INSM $106.80
  • CASY $453.00
  • AVG Volume (30 Days)
  • INSM 6.2M
  • CASY 490.8K
  • Earning Date
  • INSM 08-07-2025
  • CASY 06-09-2025
  • Dividend Yield
  • INSM N/A
  • CASY 0.45%
  • EPS Growth
  • INSM N/A
  • CASY 9.01
  • EPS
  • INSM N/A
  • CASY 14.64
  • Revenue
  • INSM $381,030,000.00
  • CASY $15,940,899,000.00
  • Revenue This Year
  • INSM $28.03
  • CASY $11.07
  • Revenue Next Year
  • INSM $120.54
  • CASY $6.33
  • P/E Ratio
  • INSM N/A
  • CASY $34.93
  • Revenue Growth
  • INSM 20.77
  • CASY 7.25
  • 52 Week Low
  • INSM $60.40
  • CASY $350.52
  • 52 Week High
  • INSM $106.83
  • CASY $514.32
  • Technical
  • Relative Strength Index (RSI)
  • INSM 62.07
  • CASY 68.98
  • Support Level
  • INSM $98.85
  • CASY $499.81
  • Resistance Level
  • INSM $106.83
  • CASY $512.78
  • Average True Range (ATR)
  • INSM 3.17
  • CASY 9.62
  • MACD
  • INSM -0.86
  • CASY -0.13
  • Stochastic Oscillator
  • INSM 20.61
  • CASY 82.40

About INSM Insmed Incorporated

Insmed Inc is a biopharmaceutical company transforming the lives of patients with serious and rare diseases. The company's first commercial product is ARIKAYCE (amikacin liposome inhalation suspension), approved in the US for the treatment of Mycobacterium Avium Complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. It is also developing Brensocatib, an oral reversible dipeptidyl peptidase 1 inhibitor for bronchiectasis and other neutrophil-mediated diseases, and Treprostinil Palmitil Inhalation Powder, an inhaled treprostinil prodrug for pulmonary hypertension linked to interstitial lung disease and pulmonary arterial hypertension.

About CASY Casey's General Stores Inc.

Casey's serves as the nation's third-largest convenience store chain with its 2,900 locations primarily positioned in the Midwest United States. About half of Casey's stores are located in rural towns with populations under 5,000. While fueling stations serve as a key traffic driver, about two thirds of the company's gross profit stems from in-store sales of grocery items, prepared meals, and general merchandise. Casey's owns more than 90% of its stores and operates most of its warehousing and distribution processes internally.

Share on Social Networks: